Aleksei Shkurat
Research Subjects
Aleksei Shkurat has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Andrey A. Lebedinets
Leningrad Regional Clinical Hospital
4 shared publications - Ilya Tsimafeyeu
Bureau for Cancer Research - BUCARE, New York, NY 10032, USA
4 shared publications - Alexey S. Kalpinskiy
P. A. Hertsen Moscow Oncology Research Institute — branch of the National Medical Research Radiological Center, Ministry of Health of Russia
3 shared publications - Vladislav V. Petkau
Sverdlovsk Regional Oncological Dispensary; Ural State Medical University
3 shared publications - E. L. Parsadanova
Sakhalin Regional Clinical Oncology Dispensary
2 shared publications - Mark Igorevich Gluzman
St. Petersburg State University; City Clinical Oncology Dispensary
2 shared publications
Latest Publications
- Open Access
- 4 March 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
Analysis of the Efficacy and Safety of Avelumab Maintenance Therapy in Subgroups of Patients with Metastatic Urothelial Carcinoma in Real-World Practice (RAVE-Bladder Study)
Objective: To evaluate the efficacy and safety of avelumab maintenance therapy in patients with metastatic urothelial carcinoma (UC) in real-world practice. Methods: This ambispective study included patients with metastatic UC and measurable tumor lesions, without progression during and after first-line platinum-based chemotherapy (CHT), who received avelumab maintenance therapy (800 mg IV every 2 weeks). The primary endpoint of the study was overall survival (OS). Results: The study included 110 patients, with a predominance of men (81 %). The median age of all patients was 65 (range, 36–84) years. With a median follow-up of 11.9 months, the median OS was not reached; the one-year OS was 78.7 %. The median progression-free survival (PFS) was 9.5 months (95 % CI, 7.8–11.2 months). The objective response rate (ORR) to first-line chemotherapy was 48.2 %. Of the 97 patients with an evaluated objective response, 38 (39.2 %) demonstrated additional objective responses to avelumab therapy (16 complete and 22 partial responses). Grade 3 adverse events during avelumab therapy were observed in 11.8 % of patients. Conclusions: The efficacy and safety of avelumab maintenance therapy in real-world practice are comparable to those in the pivotal study.
- 4 March 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
Open AccessAnalysis of the Efficacy and Safety of Avelumab Maintenance Therapy in Subgroups of Patients with Metastatic Urothelial Carcinoma in Real-World Practice (RAVE-Bladder Study)
Objective: To evaluate the efficacy and safety of avelumab maintenance therapy in patients with metastatic urothelial carcinoma (UC) in real-world practice. Methods: This ambispective study included patients with metastatic UC and measurable tumor lesions, without progression during and after first-line platinum-based chemotherapy (CHT), who received avelumab maintenance therapy (800 mg IV every 2 weeks). The primary endpoint of the study was overall survival (OS). Results: The study included 110 patients, with a predominance of men (81 %). The median age of all patients was 65 (range, 36–84) years. With a median follow-up of 11.9 months, the median OS was not reached; the one-year OS was 78.7 %. The median progression-free survival (PFS) was 9.5 months (95 % CI, 7.8–11.2 months). The objective response rate (ORR) to first-line chemotherapy was 48.2 %. Of the 97 patients with an evaluated objective response, 38 (39.2 %) demonstrated additional objective responses to avelumab therapy (16 complete and 22 partial responses). Grade 3 adverse events during avelumab therapy were observed in 11.8 % of patients. Conclusions: The efficacy and safety of avelumab maintenance therapy in real-world practice are comparable to those in the pivotal study.
- Open Access
- 27 February 2026
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (4) , 113-121
The Leningrad Regional Clinical Hospital’s own experience of treating non-clear cell renal cell carcinoma with a combination of lenvatinib and pembrolizumab
Background. Non-clear cell renal cell carcinoma (nRCC) is a heterogeneous group of malignancies, accounting for approximately 15–20 % of all kidney tumors. Results of the KEYNOTE-B61 phase II trial demonstrated high antitumor activity and a favorable safety profile for the combination of lenvatinib and pembrolizumab in patients with nRCC. Due to these clinically significant results, the combination of lenvatinib and pembrolizumab has been included in international and Russian guidelines, becoming the preferred first-line treatment for metastatic nRCC. Aim. To confirm the efficacy of the combination of lenvatinib and pembrolizumab in real-world clinical practice at the Leningrad Regional Clinical Hospital in patients with nRCC. Materials and methods. In this study, we conducted a retrospective analysis of real-world clinical data describing 10 patients with nRCC treated with combination therapy of lenvatinib and pembrolizumab. Results. The objective response rate was 40 %, including 10 % of complete responses. Median progression-free survival was not achieved (follow-up 36-49 months for most patients). At the last follow-up, all patients remained progression-free. No new safety signals were identified. Conclusion. The experience of the Leningrad Regional Clinical Hospital with the combination of lenvatinib plus pembrolizumab for the treatment of nRCC has confirmed its efficacy and safety in real-world clinical practice in a Russian patient cohort. The safety profile was predictable and manageable, with no treatment-related lethal outcomes. These findings support that the combination of lenvatinib plus pembrolizumab should be considered a standard first-line therapy for patients with advanced nRCC.
- 27 February 2026
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (4) , 113-121
Open AccessThe Leningrad Regional Clinical Hospital’s own experience of treating non-clear cell renal cell carcinoma with a combination of lenvatinib and pembrolizumab
Background. Non-clear cell renal cell carcinoma (nRCC) is a heterogeneous group of malignancies, accounting for approximately 15–20 % of all kidney tumors. Results of the KEYNOTE-B61 phase II trial demonstrated high antitumor activity and a favorable safety profile for the combination of lenvatinib and pembrolizumab in patients with nRCC. Due to these clinically significant results, the combination of lenvatinib and pembrolizumab has been included in international and Russian guidelines, becoming the preferred first-line treatment for metastatic nRCC. Aim. To confirm the efficacy of the combination of lenvatinib and pembrolizumab in real-world clinical practice at the Leningrad Regional Clinical Hospital in patients with nRCC. Materials and methods. In this study, we conducted a retrospective analysis of real-world clinical data describing 10 patients with nRCC treated with combination therapy of lenvatinib and pembrolizumab. Results. The objective response rate was 40 %, including 10 % of complete responses. Median progression-free survival was not achieved (follow-up 36-49 months for most patients). At the last follow-up, all patients remained progression-free. No new safety signals were identified. Conclusion. The experience of the Leningrad Regional Clinical Hospital with the combination of lenvatinib plus pembrolizumab for the treatment of nRCC has confirmed its efficacy and safety in real-world clinical practice in a Russian patient cohort. The safety profile was predictable and manageable, with no treatment-related lethal outcomes. These findings support that the combination of lenvatinib plus pembrolizumab should be considered a standard first-line therapy for patients with advanced nRCC.
- 28 August 2025
- Published by Wiley in BJU International
- Vol. 137 (1) , 72-75
Maintenance avelumab in metastatic urothelial carcinoma: do tumour site and previous surgery matter?
- 28 August 2025
- Published by Wiley in BJU International
- Vol. 137 (1) , 72-75
Maintenance avelumab in metastatic urothelial carcinoma: do tumour site and previous surgery matter?
- Open Access
- 6 August 2025
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (2) , 25-32
Efficacy of avelumab and axitinib depending on disease burden in patients with metastatic renal cell carcinoma: a subgroup analysis of the RAVE-Renal trial
Background. Immunotherapies and targeted therapies have demonstrated significant efficacy in prospective randomized trials establishing them as the standard of care for patients with metastatic renal cell carcinoma.This analysis, part of the RAVE-Renal real-world study, aimed to evaluate the effectiveness of avelumab plus axitinib based on disease burden and the presence of liver and bone metastases.Materials and methods. The RAVE-Renal trial was a multicenter, ambispective study that included treatment-naïve patients with histologically confirmed metastatic renal cell carcinoma and measurable lesions. Patients were treated with avelumab (800 mg every two weeks) and axitinib (5 mg twice daily). Primary endpoints were median progressionfree survival (PFS) and objective response rate (ORR). Secondary endpoints included median overall survival, 1-year overall survival, and safety. Subgroup analyses evaluated median PFS and ORR in patients with ³2 organ metastases, bone metastases, and liver metastases.Results. A total of 125 patients from 13 centers were enrolled, with median follow-up of 16.1 months and median age of 61 years. Based on IMDC (International Metastatic RCC Database Consortium) risk categories, 35.3 % had favorable, 49 % had intermediate, and 15.7 % had poor prognosis. The overall population demonstrated median PFS of 14.9 months and ORR of 44.3 %. Among patients with ³2 organ metastases, median PFS was 13.0 months, and ORR was 36.7 % (all p 0.05). In those with bone metastases, median PFS was 6.5 months (p = 0.160), and ORR was 23.5 % (p = 0.0148). For patients with liver metastases, median PFS was 17.6 months, and ORR was 45.5 % (all p 0.05).Conclusion. The combination of avelumab and axitinib demonstrated consistent efficacy in patients with advanced disease including those with liver and bone metastases. These findings suggest the regimen’s broad applicability and suitability in real-world clinical practice.
- 6 August 2025
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (2) , 25-32
Open AccessEfficacy of avelumab and axitinib depending on disease burden in patients with metastatic renal cell carcinoma: a subgroup analysis of the RAVE-Renal trial
Background. Immunotherapies and targeted therapies have demonstrated significant efficacy in prospective randomized trials establishing them as the standard of care for patients with metastatic renal cell carcinoma.This analysis, part of the RAVE-Renal real-world study, aimed to evaluate the effectiveness of avelumab plus axitinib based on disease burden and the presence of liver and bone metastases.Materials and methods. The RAVE-Renal trial was a multicenter, ambispective study that included treatment-naïve patients with histologically confirmed metastatic renal cell carcinoma and measurable lesions. Patients were treated with avelumab (800 mg every two weeks) and axitinib (5 mg twice daily). Primary endpoints were median progressionfree survival (PFS) and objective response rate (ORR). Secondary endpoints included median overall survival, 1-year overall survival, and safety. Subgroup analyses evaluated median PFS and ORR in patients with ³2 organ metastases, bone metastases, and liver metastases.Results. A total of 125 patients from 13 centers were enrolled, with median follow-up of 16.1 months and median age of 61 years. Based on IMDC (International Metastatic RCC Database Consortium) risk categories, 35.3 % had favorable, 49 % had intermediate, and 15.7 % had poor prognosis. The overall population demonstrated median PFS of 14.9 months and ORR of 44.3 %. Among patients with ³2 organ metastases, median PFS was 13.0 months, and ORR was 36.7 % (all p 0.05). In those with bone metastases, median PFS was 6.5 months (p = 0.160), and ORR was 23.5 % (p = 0.0148). For patients with liver metastases, median PFS was 17.6 months, and ORR was 45.5 % (all p 0.05).Conclusion. The combination of avelumab and axitinib demonstrated consistent efficacy in patients with advanced disease including those with liver and bone metastases. These findings suggest the regimen’s broad applicability and suitability in real-world clinical practice.
- Open Access
- 27 December 2024
- Published by MDPI AG in Current Oncology
- Vol. 32 (1) , 11
Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study
Background: The RAVE-Renal study was conducted to evaluate the real-world efficacy and safety of avelumab plus axitinib as a first-line therapy for patients with metastatic renal cell carcinoma (mRCC). Methods: RAVE-Renal was a multicenter, noninterventional, ambispective study with both retrospective and prospective components. The study included adult patients with histologically confirmed mRCC, measurable disease per RECIST version 1.1, and no prior systemic therapy. Patients received avelumab (800 mg intravenously every 2 weeks) plus axitinib (5 mg orally twice daily). The primary endpoints were median progression-free survival (PFS) and objective response rate (ORR). The secondary endpoints included median OS, 1-year overall survival (OS) rate, and safety. Results: A total of 125 patients from 13 sites were enrolled, with a median follow-up of 16.1 months. The median age was 61.0 years. The study population comprised 35.3% favorable, 49% intermediate, and 15.7% poor IMDC risk patients. The median PFS was 14.9 months (95% CI, 11.72–19.08). The ORR was 44.3% (95% CI, 32.5–56.1). The clinical benefit rate was 93.4%. The 1-year OS rate was 71.2%, with the median OS not reached. Any-grade treatment-related adverse events (TRAEs) occurred in 99 (79.2%) cases, including grade ≥3 TRAEs in 24 (19.2%). Conclusions: Avelumab in combination with axitinib showed clinical benefits in a real-world setting, consistent with findings from a pivotal trial. The regimen was effective and well tolerated across various patient subgroups.
- 27 December 2024
- Published by MDPI AG in Current Oncology
- Vol. 32 (1) , 11
Open AccessReal-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study
Background: The RAVE-Renal study was conducted to evaluate the real-world efficacy and safety of avelumab plus axitinib as a first-line therapy for patients with metastatic renal cell carcinoma (mRCC). Methods: RAVE-Renal was a multicenter, noninterventional, ambispective study with both retrospective and prospective components. The study included adult patients with histologically confirmed mRCC, measurable disease per RECIST version 1.1, and no prior systemic therapy. Patients received avelumab (800 mg intravenously every 2 weeks) plus axitinib (5 mg orally twice daily). The primary endpoints were median progression-free survival (PFS) and objective response rate (ORR). The secondary endpoints included median OS, 1-year overall survival (OS) rate, and safety. Results: A total of 125 patients from 13 sites were enrolled, with a median follow-up of 16.1 months. The median age was 61.0 years. The study population comprised 35.3% favorable, 49% intermediate, and 15.7% poor IMDC risk patients. The median PFS was 14.9 months (95% CI, 11.72–19.08). The ORR was 44.3% (95% CI, 32.5–56.1). The clinical benefit rate was 93.4%. The 1-year OS rate was 71.2%, with the median OS not reached. Any-grade treatment-related adverse events (TRAEs) occurred in 99 (79.2%) cases, including grade ≥3 TRAEs in 24 (19.2%). Conclusions: Avelumab in combination with axitinib showed clinical benefits in a real-world setting, consistent with findings from a pivotal trial. The regimen was effective and well tolerated across various patient subgroups.